Good morning,
I have always been apprehensive investing in penny arcade Bio-Companys for the obvious reason. They are dilutive nightmares without much success.
I have made an exception with BLEG. I was led to this company by a very good friend and really wasn't impressed, but after considerable DD, I have decided to take a modest position.
First, I have to say that the share structure is very attractive for a Bio company at A/S 900m O/S 676m. The very promising share reduction shows the company's intent is to maximize ROI for share shareholders and this is a big deal. Also, the CEO holds majority and the protection against greenmailing is well in place. This protection is a mechanism against hostile takeovers maneuvering through backdoor schemes. Very promising.
The attorney letter from last year bla,bla,bla is all good and basically denotes all is well.
Net income for 2023 at 3.8$m is very nice indeed and current assets is well in line with a solid MC of 2.2$m, which incidentally allows for a solid growth moving forward with a very limit on any dilutive impact. I like it!
Assets verses Liabilities is well in line and very reasonable to say the least. Very positive indeed.
The strategic acquisition of Sycamore BioPharma, Inc, a distinguished developer of plant-based pharmaceuticals. This strategic milestone not only fortifies Branded Legacy's standing as a prominent player in the biotech sector but also secures assets exceeding $2 million, along with key personnel crucial for advancing clinical trials following this successful union. This by far is most promising!
White paper concept is usually written by a company to illustrate their knowledge and expertise through facts and evidence, but it should not advertise or endorse a company’s product. White papers are designed to present persuasive research, detail a problem at hand, and provide a solution and is essential for the further guiding to move through the FDA. Company is on the right track and should elevate the ROI for shareholding understanding.
The company is on the path to build a solid foundation to retail their product through white label contracts and this only will propel the company a rev stream in a fast-track setting and the exposure is fairly optimistic and should bode well in the near-term going out in the long run for us shareholders.
The company isn't shy about keeping shareholders informed and I expect major announcement on retail venues in the coming months through the end of year 2024.
I see a price target .01 within the 2024 year and will give us a MC of 10$m which in my opinion is very doable and reasonable.
Solid buying opportunity at .004-.007
Have a good day
varok
Bullish
